Company Filing History:
Years Active: 2014
Title: Michael J Difilippantonio: Innovator in Cancer Research
Introduction
Michael J Difilippantonio is a notable inventor based in Rockville, MD (US). He has made significant contributions to the field of cancer research, particularly in understanding the responsiveness of rectal adenocarcinomas to treatment. His work has implications for improving patient outcomes through personalized medicine.
Latest Patents
Michael holds a patent for a composition that detects the response of rectal adenocarcinomas to radiochemotherapy. This innovative patent, titled "Composition for detecting the response of rectal adenocarcinomas to radiochemotherapy," utilizes a cDNA array consisting of 9984 genes for expression profiling in rectal adenocarcinoma. The expression data obtained from this array were correlated with the responsiveness to chemotherapy followed by radiotherapy. Notably, a set of 54 genes was identified as differentially expressed in responders versus non-responders. These genes may serve as prognostic markers to determine whether a rectal adenocarcinoma is responsive to radiochemotherapy.
Career Highlights
Michael is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His role at this prestigious institution allows him to engage in cutting-edge research that has the potential to transform cancer treatment protocols.
Collaborations
Throughout his career, Michael has collaborated with esteemed colleagues, including Thomas Ried and Bijan-Michael Ghadimi. These collaborations have further enriched his research and contributed to advancements in the field.
Conclusion
Michael J Difilippantonio's work exemplifies the intersection of innovation and healthcare, particularly in cancer research. His contributions through patenting and collaboration are paving the way for improved treatment strategies for rectal adenocarcinoma.